Yunying Cui

505 total citations
29 papers, 337 citations indexed

About

Yunying Cui is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Yunying Cui has authored 29 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 21 papers in Endocrinology, Diabetes and Metabolism and 14 papers in Cancer Research. Recurrent topics in Yunying Cui's work include Adrenal and Paraganglionic Tumors (24 papers), Hormonal Regulation and Hypertension (15 papers) and Cancer, Hypoxia, and Metabolism (14 papers). Yunying Cui is often cited by papers focused on Adrenal and Paraganglionic Tumors (24 papers), Hormonal Regulation and Hypertension (15 papers) and Cancer, Hypoxia, and Metabolism (14 papers). Yunying Cui collaborates with scholars based in China. Yunying Cui's co-authors include Fen Wang, Anli Tong, Xin Li, Jing Tian, Yan Xue, Jie Chen, Yuxiu Li, Chunyan Li, Yushi Zhang and Jun Jiang and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Annals of the New York Academy of Sciences.

In The Last Decade

Yunying Cui

26 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yunying Cui China 11 234 151 78 77 32 29 337
Somya Verma United States 7 150 0.6× 255 1.7× 107 1.4× 55 0.7× 35 1.1× 10 369
Jan Schovánek Czechia 11 119 0.5× 140 0.9× 51 0.7× 96 1.2× 15 0.5× 32 298
Valentina Crudo United States 8 404 1.7× 419 2.8× 70 0.9× 50 0.6× 28 0.9× 17 529
Azadeh A. Carr United States 12 221 0.9× 166 1.1× 59 0.8× 40 0.5× 25 0.8× 24 348
Manjunath Goroshi India 12 157 0.7× 155 1.0× 20 0.3× 51 0.7× 23 0.7× 31 284
Guilherme Asmar Alencar Brazil 7 232 1.0× 204 1.4× 45 0.6× 128 1.7× 10 0.3× 9 298
Shun‐Yu Chi Taiwan 10 184 0.8× 157 1.0× 35 0.4× 28 0.4× 34 1.1× 38 297
Anne Tybjærg-Hansen Denmark 4 131 0.6× 84 0.6× 87 1.1× 56 0.7× 20 0.6× 6 319
Maria Albuja‐Cruz United States 11 220 0.9× 194 1.3× 27 0.3× 88 1.1× 10 0.3× 17 301
Tarek Abdel‐Aziz United Kingdom 9 133 0.6× 104 0.7× 26 0.3× 33 0.4× 21 0.7× 27 226

Countries citing papers authored by Yunying Cui

Since Specialization
Citations

This map shows the geographic impact of Yunying Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunying Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunying Cui more than expected).

Fields of papers citing papers by Yunying Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunying Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunying Cui. The network helps show where Yunying Cui may publish in the future.

Co-authorship network of co-authors of Yunying Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Yunying Cui. A scholar is included among the top collaborators of Yunying Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunying Cui. Yunying Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Wenqian, et al.. (2025). PBK as a Potential Biomarker and Therapeutic Target for Metastatic Pheochromocytomas and Paragangliomas. The Journal of Clinical Endocrinology & Metabolism. 111(4). 953–963. 1 indexed citations
2.
Cui, Yunying, Wenqian Zhang, Liu He, et al.. (2025). A study on the efficacy and safety of anlotinib in patients with metastatic pheochromocytoma and paraganglioma. Endocrine Related Cancer. 32(12).
3.
Cui, Yunying, et al.. (2024). Pheochromocytoma in von Hippel‐Lindau Disease: Clinical Features and Comparison With Sporadic Pheochromocytoma. Clinical Endocrinology. 102(3). 355–361.
4.
Zhang, Wenqian, Jie Yu, Yue Zhou, et al.. (2024). Glucose Disorders in Patients With Pheochromocytoma/Paraganglioma: Profile and Influence Effects in a Large Cohort With 705 Patients. Endocrine Practice. 31(3). 269–277. 2 indexed citations
5.
Gao, Yinjie, et al.. (2023). Development and internal validation of a novel predictive model for SDHB mutations in pheochromocytomas and retroperitoneal paragangliomas. Frontiers in Endocrinology. 14. 1285631–1285631. 2 indexed citations
6.
Cui, Yunying, et al.. (2022). Fumarate hydratase gene germline variants and mosaicism associated with pheochromocytoma and paraganglioma. Annals of the New York Academy of Sciences. 1516(1). 262–270. 2 indexed citations
7.
Cui, Yunying, et al.. (2022). Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas. The Journal of Clinical Endocrinology & Metabolism. 108(3). 755–766. 10 indexed citations
9.
Zhao, Meng, Fen Wang, Yunying Cui, et al.. (2022). Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma. Frontiers in Endocrinology. 13. 921645–921645. 4 indexed citations
10.
Ding, Jie, Yunying Cui, Tianyi Li, et al.. (2022). Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET/CT. European Radiology. 33(2). 996–1003. 37 indexed citations
11.
Cui, Yunying, Yinjie Gao, Xiaoyan Chang, et al.. (2021). Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes. Frontiers in Endocrinology. 12. 762548–762548. 12 indexed citations
12.
Wang, Huiping, Fen Wang, Yushi Zhang, et al.. (2021). Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings. Frontiers in Endocrinology. 12. 663096–663096. 18 indexed citations
13.
14.
Cui, Yunying, Fen Wang, Huiping Wang, et al.. (2020). Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation. Endocrine Practice. 27(4). 348–353. 5 indexed citations
16.
Cui, Yunying, Yushi Zhang, Jie Ding, et al.. (2019). A Rare Aldosterone-Producing Adenoma Detected by 68Ga-pentixafor PET-CT: A Case Report and Literature Review. Frontiers in Endocrinology. 10. 810–810. 2 indexed citations
17.
Wang, Fen, Chuan Shi, Yunying Cui, Chunyan Li, & Anli Tong. (2016). Mutation profile and treatment of Gitelman syndrome in Chinese patients. Clinical and Experimental Nephrology. 21(2). 293–299. 23 indexed citations
18.
Tong, Anli, et al.. (2016). Interaction between Angiotensin II and Insulin/IGF-1 Exerted a Synergistic Stimulatory Effect on ERK1/2 Activation in Adrenocortical Carcinoma H295R Cells. International Journal of Endocrinology. 2016. 1–9. 6 indexed citations
19.
Cui, Yunying, et al.. (2016). Liddle syndrome: clinical and genetic profiles. Journal of Clinical Hypertension. 19(5). 524–529. 37 indexed citations
20.
Chen, Jie, et al.. (2013). Risk factors for deep infection after total knee arthroplasty: a meta-analysis. Archives of Orthopaedic and Trauma Surgery. 133(5). 675–687. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026